Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21536801rdf:typepubmed:Citationlld:pubmed
pubmed-article:21536801lifeskim:mentionsumls-concept:C0205147lld:lifeskim
pubmed-article:21536801lifeskim:mentionsumls-concept:C0037083lld:lifeskim
pubmed-article:21536801lifeskim:mentionsumls-concept:C0031678lld:lifeskim
pubmed-article:21536801lifeskim:mentionsumls-concept:C1417530lld:lifeskim
pubmed-article:21536801lifeskim:mentionsumls-concept:C1824680lld:lifeskim
pubmed-article:21536801lifeskim:mentionsumls-concept:C1710082lld:lifeskim
pubmed-article:21536801lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:21536801lifeskim:mentionsumls-concept:C1334043lld:lifeskim
pubmed-article:21536801lifeskim:mentionsumls-concept:C2697616lld:lifeskim
pubmed-article:21536801lifeskim:mentionsumls-concept:C1533157lld:lifeskim
pubmed-article:21536801pubmed:issue11lld:pubmed
pubmed-article:21536801pubmed:dateCreated2011-5-20lld:pubmed
pubmed-article:21536801pubmed:abstractTextCD300F is known to exhibit inhibitory activity in myeloid cells through its intracellular ITIM. To investigate the effect of CD300F stimulation on TLR signaling, the human acute monocytic leukemia cell line THP-1 was treated with CD300F-specific mAbs or two synthetic peptides that represented the ITIM-like domains of CD300F. Treatment with these agents blocked TLR2-, 3-, 4-, and 9-mediated expression of proinflammatory mediators such as IL-8 and matrix metalloproteinase-9. The luciferase reporter assay in 293T cells and Western blot analysis of THP-1 cells revealed that these inhibitory actions were effective in pathways involving MyD88 and/or TRIF of TLR signaling and associated with marked suppression of I?B kinase activation, phosphorylation/degradation of I?B, and subsequent activation of NF-?B. Use of specific inhibitors and immunoprecipitation analysis further indicated that the inhibitory effects were mediated by Src homology 2 domain-containing phosphatase-1, a protein tyrosine phosphatase with inhibitory activity in hematopoietic cells. These data indicate that CD300F is an active regulator of TLR-mediated macrophage activation through its association with Src homology 2 domain-containing phosphatase-1 and that the synthetic peptides can be applied for the regulation of immune responses that are induced by TLRs.lld:pubmed
pubmed-article:21536801pubmed:languageenglld:pubmed
pubmed-article:21536801pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:citationSubsetAIMlld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21536801pubmed:statusMEDLINElld:pubmed
pubmed-article:21536801pubmed:monthJunlld:pubmed
pubmed-article:21536801pubmed:issn1550-6606lld:pubmed
pubmed-article:21536801pubmed:authorpubmed-author:LeeWon-HaWHlld:pubmed
pubmed-article:21536801pubmed:authorpubmed-author:SukKyounghoKlld:pubmed
pubmed-article:21536801pubmed:authorpubmed-author:LeeSang-MinSMlld:pubmed
pubmed-article:21536801pubmed:authorpubmed-author:KimEun-JuEJlld:pubmed
pubmed-article:21536801pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21536801pubmed:day1lld:pubmed
pubmed-article:21536801pubmed:volume186lld:pubmed
pubmed-article:21536801pubmed:ownerNLMlld:pubmed
pubmed-article:21536801pubmed:authorsCompleteYlld:pubmed
pubmed-article:21536801pubmed:pagination6296-303lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:meshHeadingpubmed-meshheading:21536801...lld:pubmed
pubmed-article:21536801pubmed:year2011lld:pubmed
pubmed-article:21536801pubmed:articleTitleCD300F blocks both MyD88 and TRIF-mediated TLR signaling through activation of Src homology region 2 domain-containing phosphatase 1.lld:pubmed
pubmed-article:21536801pubmed:affiliationSchool of Life Sciences and Biotechnology, Kyungpook National University, Daegu 702-701, Korea.lld:pubmed
pubmed-article:21536801pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21536801pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:4615entrezgene:pubmedpubmed-article:21536801lld:entrezgene
entrez-gene:5777entrezgene:pubmedpubmed-article:21536801lld:entrezgene
entrez-gene:146722entrezgene:pubmedpubmed-article:21536801lld:entrezgene
entrez-gene:148022entrezgene:pubmedpubmed-article:21536801lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:21536801lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:21536801lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:21536801lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:21536801lld:entrezgene